Background illustration for clinical trials search

Glomerulonephritis Clinical Trials

Browse 135 glomerulonephritis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

for
Mucositis, Nephrotoxicity, Ototoxicity
Location: Bronx NY, Winston-Salem NC, Seattle WA, La Jolla CA,
Sponsor: Matrix Biomed, Inc.

Sex: All

Age: 18+

Code: NCT03480971

Phase 2, Recruiting

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

for
mCRPC (Metastatic Castration-resistant Prostate Cancer),
Location: Detroit MI
Sponsor: Celcuity Inc

Sex: Male

Age: 18+

Code: NCT06190899

Phase 1, Phase 2, Recruiting
New

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

for
Immunoglobulin A Nephropathy (IgAN)
Location: Manassas VA, Miami FL, Pembroke Pines FL, Pontiac MI,
Sponsor: argenx

Sex: All

Age: 18+

Code: NCT07773727

Phase 2, Recruiting
New

Lupus Nephritis Care Pathway

for
Lupus Nephritis (LN)
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18+

Code: NCT07783152

Recruiting

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

for
Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema,
Location: Ann Arbor MI
Sponsor: University of Michigan

Sex: All

Age: 2+

Code: NCT05505500

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

for
Lupus Nephritis
Location: New York NY, Hackensack NJ, Chapel Hill NC,
Sponsor: Children's Hospital Medical Center, Cincinnati

Sex: All

Age: 8 - 20

Code: NCT05538208

Phase 2, Recruiting

Research Accelerated by You Lupus Registry

for
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN),
Location: Washington D.C. DC
Sponsor: Lupus Foundation of America

Sex: All

Age: 0+

Code: NCT06927219

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

for
SLE (Systemic Lupus), Lupus Erythematosus, Systemic,
Location: Boston MA, Chapel Hill NC, Chicago IL, New Orleans LA,
Sponsor: CRISPR Therapeutics

Sex: All

Age: 18 - 70

Code: NCT06925542

Phase 1, Recruiting

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

for
Nephrotic Syndrome in Children, Minimal Change Disease,
Location: New Hyde Park NY, Philadelphia PA
Sponsor: Northwell Health

Sex: All

Age: 3 - 17

Code: NCT05583942

Recruiting

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

for
Primary Membranous Nephropathy
Location: New York NY, Fairfax VA, Charlottesville VA,
Sponsor: Cerium Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT05696613

Phase 3, Recruiting

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

for
C3G
Location: Miami FL, Iowa City IA, Aurora CO
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 12 - 60

Code: NCT04817618

Phase 3, Recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

for
Lupus Nephritis
Location: Queens NY, Hackensack NJ, Montreal, Toronto, Atlanta GA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 5 - 17

Code: NCT05039619

Phase 2, Recruiting

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

for
Focal Segmental Glomerulosclerosis
Location: New York NY, Wilmington DE, Richmond VA, Chapel Hill NC,
Sponsor: Kaneka Medical America LLC

Sex: All

Age: 0 - 70+

Code: NCT04065438

Recruiting

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

for
Focal Segmental Glomerulosclerosis, Minimal Change Disease,
Location: Bethesda MD
Sponsor: National Human Genome Research Institute (NHGRI)

Sex: All

Age: 18 - 70+

Code: NCT06664814

Phase 2, Recruiting

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

for
FSGS
Location: New York NY, Hackensack NJ, Philadelphia PA,
Sponsor: Dimerix Bioscience Pty Ltd

Sex: All

Age: 12 - 70+

Code: NCT05183646

Phase 3, Recruiting

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

for
Lupus Nephritis, Primary Membranous Nephropathy
Location: Worcester MA, New York NY, Summit NJ, Syracuse NY,
Sponsor: Nkarta, Inc.

Sex: All

Age: 18 - 70+

Code: NCT06557265

Phase 1, Phase 2, Recruiting

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

for
Focal Segmental Glomerulosclerosis
Location: New York NY, Philadelphia PA, Wilmington DE,
Sponsor: Kaneka Medical America LLC

Sex: All

Age: 0 - 21

Code: NCT02235857

Recruiting

Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN

for
Lupus Nephritis
Location: Baltimore MD, Charlotte NC, Columbus OH, Hixson TN
Sponsor: GlaxoSmithKline

Sex: All

Age: 18+

Code: NCT06527872

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

for
Lupus Nephritis
Location: Manhasset NY, New York NY, Philadelphia PA, Hershey PA,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18+

Code: NCT05201469

Phase 2, Recruiting

Study of WAL0921 in Patients With Glomerular Kidney Diseases

for
Diabetic Nephropathies,
Location: Tamarac FL, Atlanta GA, Hinsdale IL, Houston TX,
Sponsor: Walden Biosciences

Sex: All

Age: 18 - 70+

Code: NCT06466135

Phase 2, Recruiting

Glomerulonephritis is inflammation of the glomeruli, the tiny filters inside the kidneys, and it can quietly cause protein and blood in the urine for years before kidney function declines. It includes several different diseases, such as IgA nephropathy, the most common worldwide, and FSGS, which often affects younger adults. For a long time treatment was limited to blood pressure medicines and broad immune suppression. Recent years brought the first targeted treatments for some forms, and many more are now being tested to protect kidney function before damage becomes permanent.